Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced that the first patient has been dosed in its Phase 2a clinical study of PTX-100.
The company said the Phase 2a clinical study will evaluate two dosage levels of PTX-100 in an open-label design, enrolling up to 40 patients with relapsed or refractory (r/r) Cutaneous T Cell Lymphoma (CTCL).
The study’s primary endpoint is efficacy, with safety among the secondary endpoints.
CTCL is a rare type of cancer of white blood cells, typically involved in immune function. These cells travel to and live in the skin, growing and dividing uncontrollably, attacking the skin. There are currently limited options for patients with relapsed or refractory CTCL.
Prescient Therapeutics Chief Medical Officer, Dr Marissa Lim, said, “The first patient in Prescient’s Phase 2a study has been dosed at the Linear Clinical Research site in Perth, under the care of Dr. Dejan Radeski, a consultant haematologist with a special interest in T-cell lymphoma. This marks an important step in our mission to advance additional treatment options for CTCL”